A new study published in Nature suggests that with a cellular and molecular map of the healthy human heart, experts may be able to better understand what goes wrong in cardiovascular disease.
AstraZeneca’s Farxiga improved survival chances for patients suffering from kidney disease, underscoring the medicine’s role outside the drug’s established field of diabetes.
British drugmaker AstraZeneca topped second-quarter sales and profit estimates and backed the company’s 2020 forecasts, helped by strong sales in lockdowns of a diverse product range that includes a potential coronavirus vaccine.
Pfizer Inc. filed a lawsuit seeking to require the federal government to let it help Medicare beneficiaries afford two drugs to treat a rare and sometimes fatal heart condition, and which cost $225,000 a year.
Sana Biotechnology, which launched during 2019, raised $700 million in initial financing that will be used to advance the company’s discovery and development programs that create and deliver engineered cells as a treatment for different disease types.
Shares of MyoKardia shot up more than 64 percent in trading following an announcement that the company’s lead drug mavacamten hit the mark in a Phase III study of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
All of the world’s top 10 pharmaceutical companies have established substantial operations in Ireland and from 2003 to today, there has been dynamic growth of biologics manufacturing in Ireland, according to IDA Ireland.
N.Y.-based NPXe filed a voluntary petition to reorganize under Chapter 11 of the Bankruptcy Code and is seeking permission to auction off the company’s assets.
The U.S. Food and Drug Administration declined to approve Correvio Pharma Corp.’s Brinavess to correct irregular rhythm in the upper chambers of the heart.
Apple Inc. launched an app that will let users of the company’s devices to enroll in three health studies, allowing them to share health-related data for medical research.